Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 4:36:12115.
doi: 10.3389/ti.2023.12115. eCollection 2023.

European Society of Organ Transplantation Consensus Statement on Testing for Non-Invasive Diagnosis of Kidney Allograft Rejection

Sookhyeon Park #  1 , Joana Sellares #  2 , Claire Tinel #  3 , Dany Anglicheau  4 , Oriol Bestard  2 , John J Friedewald  1
Affiliations

European Society of Organ Transplantation Consensus Statement on Testing for Non-Invasive Diagnosis of Kidney Allograft Rejection

Sookhyeon Park et al. Transpl Int. .

Abstract

To address the need for improved biomarkers for kidney transplant rejection, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in kidney transplant biomarkers to review literature pertaining to clinical and subclinical acute rejection to develop guidelines in the screening and diagnosis of acute rejection that were subsequently discussed and voted on during the Consensus Conference that took place in person in Prague. The findings and recommendations of the Working Group on Molecular Biomarkers of Kidney Transplant Rejection are presented in this article.

Keywords: biomarkers; cell-free DNA; diagnostics; gene expression; kidney transplant; non-invasive; rejection; urine chemokines.

PubMed Disclaimer

Conflict of interest statement

JF receives consulting fees from Eurofins - Transplant Genomics and grant support from Eurofins - Viracor. SP receives grant support from Eurofins - Viracor. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart summarizing the selection process of studies included in the evaluation of biomarkers for rejection in kidney transplantation. Modified figure from: [38]. For more information, visit: http://www.prisma-statement.org/.
See this image and copyright information in PMC

References

    1. Friedewald JJ, Kurian SM, Heilman RL, Whisenant TC, Poggio ED, Marsh C, et al. Development and Clinical Validity of a Novel Blood-Based Molecular Biomarker for Subclinical Acute Rejection Following Kidney Transplant. Am J Transpl (2019) 19:98–109. 10.1111/ajt.15011 - DOI - PMC - PubMed
    1. Sigdel TK, Archila FA, Constantin T, Prins SA, Liberto J, Damm I, et al. Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR. J Clin Med (2018) 8:19. 10.3390/jcm8010019 - DOI - PMC - PubMed
    1. Bu L, Gupta G, Pai A, Anand S, Stites E, Moinuddin I, et al. Clinical Outcomes From the Assessing Donor-Derived Cell-Free DNA Monitoring Insights of Kidney Allografts With Longitudinal Surveillance (ADMIRAL) Study. Kidney Int (2022) 101:793–803. 10.1016/j.kint.2021.11.034 - DOI - PubMed
    1. Zhang W, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, et al. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. J Am Soc Nephrol (2019) 30:1481–94. 10.1681/ASN.2018111098 - DOI - PMC - PubMed
    1. Bouamar R, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B, et al. Tacrolimus Predose Concentrations Do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis From Three Randomized-Controlled Clinical Trials(†). Am J Transpl (2013) 13:1253–61. 10.1111/ajt.12191 - DOI - PubMed

Publication types